C50 C61
Conditions
Interventions
Group 1: - Breast and prostate cancer patients who received radiotherapy are followed up annually for radiotherapy related side effects and complete a questionnaire on quality of life/patient reported
Sponsors
Deutsches Krebsforschungszentrum (DKFZ) / German Cancer Research Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Adult breast or prostate cancer patients who received radiotherapy and have participated in the REQUITE study in Germany, Italy, Spain, UK and who are alive at re-contact - Willingness and ability to comply with at least one scheduled visit - The capacity to understand the patient information sheet and the ability to provide written informed consent
Exclusion criteria
Exclusion criteria: - Re-irradiation of the region of initial radiotherapy (including contralateral breast) - Any breast surgery after initial RT, mastectomy patients (including contralateral breast) - Mental disability or patient otherwise unable to give informed consent and/or complete patient questionnaires - Known HIV infection, hepatitis B or hepatitis C not eligible for sample collection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Breast: Breast toxicities after a minimum of 3 years after radiotherapy - Prostate gastro-intestinal (GI): Gastrointestinal toxicity after a minimum of 3 years after radiotherapy - Prostate genito-urinary (GU): Urinary toxicity after a minimum of 3 years after radiotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| - Other toxicity endpoints including but not limited to: cosmesis, vascular changes, pain (breast); erectile dysfunction (prostate) - Patient reported outcomes - Quality of life, fatigue | — |
Countries
Germany, Italy, Spain, United Kingdom
Contacts
Public ContactJenny Chang-Claude
Deutsches Krebsforschungszentrum (DKFZ)
Outcome results
None listed